Dramatic Reduction in Tumour Size in Hepatocellular Carcinoma Patients on Thalidomide Therapy

Demeria, Denny; Birchall, I. W. J.; Bain, Vincent G.

doi:10.1155/2007/128792

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, by extracting data of survival rates at different follow-up, the synthesized results determined that thalidomide plus TACE had superior efficacy at 6, 12, 18, 24, 36 months, when compared with TACE alone. Indeed, several clinical trials[ 19 , 66 ] and experimental studies [ 4 , 24 ] also confirm the anti-tumor effects of thalidomide in HCC, and the results are encouraging.…”

Section: Discussionmentioning

confidence: 93%

Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis

Cao

Liu

et al. 2017

Oncotarget

View full text Add to dashboard Cite

ObjectiveTranscatheter arterial chemoembolization (TACE) and thalidomide have been used for treating primary hepatocellular carcinoma(HCC). This study aims to evaluate the clinical efficacy and safety of thalidomide and TACE in primary HCC.MethodsRandomized controlled trials(RCTs) about efficacy and safety of thalidomide combined with TACE for primary HCC were identified from the Cochrane Library, Pubmed, Embase, CNKI, and Wan Fang until August, 2016. The retrieved trials were reviewed and the data were extracted by two reviewers, independently. Combined analyses of survival rates, overall response rate(ORR), disease control rate(DCR), changes of KPS, parameters of cellular immunity and vascular endothelial growth factor(VEGF), and adverse events were performed using RevMan 5.3 software.ResultsA total of 23 RCTs involving 1836 patients were included. The results showed that thalidomide plus TACE was significantly superior in increasing 6-month survival rate(OR=1.79, 95% CI:1.02-3.15, P=0.04), 1-year survival rate(OR=1.76, 95% CI:1.38-2.24, P<0.0001), 1.5-year survival rate(OR=4.72, 95% CI:2.64-8.43, P<0.001), 2-year survival rate(OR=1.78, 95% CI:1.37-2.30, P<0.001), ORR(OR=1.89, 95% CI:1.48-2.42, P<0.0001), DCR(OR=2.62, 95% CI:1.90-3.63, P<0.001), improvement in cellular immunity(MD=0.63, 95% CI:0.45-0.80, P<0.0001), and reduction of VEGF(MD=-119.71, 95% CI:-135.75—103.68, P<0.0001), when compared with TACE group. The incidences of gastrointestinal reactions, myelosuppression, and liver dysfunction were similar between combination group and TACE group(P>0.05). However, compared to TACE, the combination of thalidomide and TACE had a higher incidence of drug rash(OR=6.35, 95% CI:2.75-14.68, P<0.0001).ConclusionOur findings suggest that thalidomide combined with TACE shows better clinical efficacy and tolerable adverse events in patients with primary HCC when compared with TACE alone.

show abstract

Section: Discussionmentioning

confidence: 93%

Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis

Cao

Liu

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…In another report, the complete response was observed in a 62‐year‐old man with chronic hepatitis C and metastasis to multiple lymph nodes and to the peritoneum [5]; he had received thalidomide 200–300 mg/day and had remained in a remission state for more than 11 months. Demeria et al [6] administered 100 mg thalidomide once daily to a 73‐year‐old man with multiple HCCs. Although a dramatic reduction in the tumor size was seen after 1 month of therapy, he succumbed to tumor recurrence 17 months after the initial diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Thalidomide induces complete remission of advanced hepatocellular carcinoma

Chien

2014

Adv in Digestive Medicine

View full text Add to dashboard Cite

Summary Hepatocellular carcinoma (HCC) is one of the most prevalent human cancers in the world, but its prognosis is extremely poor. HCC is considered a hypervascular tumor. Thalidomide, which has been known to inhibit growth factor‐induced neovascularization, is a convenient alternative to target therapy such as sorafenib. We report a 65‐year‐old male patient with alcoholic liver cirrhosis that was diagnosed having multiple HCCs during surveillance. The patient was assessed as inoperable and unsuited for transhepatic arterial chemoembolization or systemic chemotherapy. After discussing the therapeutic alternatives, he decided to receive low‐dose thalidomide (100 mg daily) therapy. Fortunately, follow‐up liver biochemical tests, serum α‐fetoprotein level, and dynamic computed tomography showed complete remission of the HCCs 4.5 months after thalidomide treatment and this was documented for more than 22 months without evidence of tumor recurrence.

show abstract

Dramatic Reduction in Tumour Size in Hepatocellular Carcinoma Patients on Thalidomide Therapy

Cited by 2 publications

References 7 publications

Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis

Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis

Thalidomide induces complete remission of advanced hepatocellular carcinoma

Contact Info

Product

Resources

About